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Abstract

DEVELOPMENT OF DUAL-PATHWAY INHIBITORS OF Raf/MEK/ERK AND
PI3K/AKT SIGNALING PATHWAYS.
By Sasha Fraser, B.Sc.
A thesis submitted in partial fulfillment of the requirements for the degree of
Master of Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2011.
Major Director: Shijun Zhang, Ph. D., Medicinal Chemistry.

In the present study, we designed a new chemical template that contains
an oxindole moiety as potential dual-pathway inhibitors of the Raf/MEK/ERK and
PI3K/Akt signaling pathways. The design hypothesis is to evaluate whether the
oxindole ring system will approximately orient functional groups in a similar
manner to the thiazolidinedione moiety, and thus maintain biological activity as
dual-pathway inhibitors of the Raf/MEK/ERK and PI3K/Akt signaling pathways.
Furthermore, the oxindole ring will provide the flexibility to allow the introduction
of

various

substituents

on

the

oxindole

moiety,

thereby

facilitating

comprehensive SAR studies to further explore the biological activity.
The oxindole analogs were biologically characterized by employing human
leukemia U937 cells. Anti-proliferation activity using the 3-[4, 5-dimethylthiazol-2yl]-2, 5-diphenyltetrazolium (MTT) assay was tested, and all of the designed
1

compounds exhibited activity against the growth of U937 cells with micromolar
potency. Notably, compared to lead compound 1, the oxindole analogs, exhibited
improved anti-proliferation activity (4-fold increase). Western blot analysis
revealed that the expression of critical components of the pathways such as pERK and p-Akt, were consistently suppressed by these oxindole analogs, thus
correlating the inhibition of the two signaling pathways with the anti-proliferative
activity. The apoptotic effects of the most potent oxindole compounds were
evaluated using flow cytometry to obtain preliminary mechanistic information.
The results demonstrated that the compounds induced significant early- and latestage apoptosis.

2

1. Literature Review
Signal transduction pathways have long been recognized for their central
role in the regulation of mammalian cellular programs in response to extracellular
cues. As it pertains to the fine-tuning of important survival functions including cell
cycle progression, apoptosis, and protein synthesis and growth, it is well
documented that the Raf/MEK/extracellular signal-regulated kinase (ERK) and
the phosphatidylinositol 3-kinase (PI3K)/Akt transduction pathways are among
the key players. 1,2
Notably, initial seminal studies have shown that mutations can occur at
genes encoding for some of these pathway components, as well as at upstream
molecules that transmit their signal through the pathways.1,3 Several reports have
correlated the aberrations with the induction of malignant phenotypes. Currently,
it is estimated that the pathways account for more than 30% all human cancer,
most often in haematopoietic malignancies.

4

Given the high frequency of

deregulation, the pathways have been considered key targets for therapeutic
intervention and, a diverse range of small molecules have been developed to the
target key nodes unique to the Raf/MEK/ERK and PI3K/Akt pathways.5,6 This has
created a platform for a more selective targeted approach to cancer
chemotherapy, a shift from the existing anti-mitotic cancer agents that crudely
interfere with the basic machinery of DNA synthesis and cell division such as
taxol and vinblastine.

3

1.1 Oncogenic Signaling
The dependence of transformed cells on the signaling pathways has been
extensively investigated. As summarized by Hanahan and Weinberg, the current
concensus is that a fully malignant invasive tumor requires deregulation of at
least six physiological processes which confers:7
x

Acquired self-sufficiency and independence of growth signals

x

Insensitivity to growth inhibitor signals

x

Circumvention of programmed cell death

x

Limitless replicative potential and telomere erosion

x

Sustained angiogenesis for nutrient supply

x

Invasion and Metastasis

Figure 1: Simplified representation of the increased cell proliferation and cancer cell
survival

Abnormalities in the Raf/MEK/ERK and the PI3K/Akt pathways impinge on
all of these processes directly or indirectly. Generally, the constraints placed on
proliferative response by the pathways are perturbed. In addition to intrinsic point
mutations of signal transducer molecule such as Ras, the abnormalities include
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activating mutations of RTK and chromosomal translocation, as well as overexpression of normal gene products. Although, cancers are diverse with multiple
possible combinations of defects; in most cases, deregulated signaling provide
the basal platform for neoplastic progression (Figure 1).3 As in the case of the
erosion of telomeres, although it is one of the six hallmarks of cancer, it is a
result of repeated cell division. Further mutations are essentially for additional
growth advantage for progeny. Angiogenesis allows development of nurturing
vasculature from blood vessels of adjacent cells. The acquired self-reliance
enables cell to colonize distant cells, most frequently bone and lymph node in a
process termed metastasis. Due to the direct connect between uncontrolled
growth and the latter complication usually leading to death; growth inhibition, cell
cycle arrest and apoptosis of transformed cells is the desired endpoint of anticancer agents.8

5

1.2 The Raf/MEK/ERK Pathway
The Raf/MEK/ERK pathway is the prototypic pathway of the evolutionary
conserved family of mitogen-DFWLYDWHG SURWHLQ NLQDVHV 0$3. ¶s. It couples
signals from many receptors, both membrane bound (e.g. receptor tyrosine
kinases) and intracellular tyrosine kinases (e.g. ABL), to transcription factors
which serve as the terminal effectors in the modulation of gene expression
(Figure 2). 1,4

Figure   2: Schematic diagram of the activation of the Raf/ MEK/ ERK pathway and its
downstream targets.

Historically, the Raf/MEK/ERK pathway has been synonymous with cell
6

cycle progression, but more recently pathway has been associated with the
phosphorylation of several proteins involved in apoptosis. The core module of the
pathway is three tiered and consists: Raf, a MAPK kinase kinase (MAPKKK) that
can phosphorylate and activate MEK, a MAPK kinase (MAPKK), which in turn
phosphorylate and activate ERK, a MAPK.9 Growth factors are largely
responsible for pathway stimulation. However, the pathway can be activated to
some extent by ligands for heterotrimeric G protein-coupled receptors (GPCRs)
and cytokines among other stimuli. The ligand-mediated activation via receptor
tyrosine kinases triggers the formation of Ras in its GTP bound conformation.
Subsequently, stimulating the translocation of Raf the cell membrane.
Aberrant activation of this pathway is a common occurrence. Importantly,
core modules 5DV DQG 5DI ZHUH ILUVW GLVFRYHUHG LQ WKH ¶V DV WUDQVIRUPLQJ
oncogenes of the murine sarcoma virus.10 This landmark finding of the cellular
origin of retroviral oncogene has contributed greatly to delineating molecular
changes that drive tumorigenesis. The seminal link between the pathways and
human cancers has been substantiated by 25 years of research. Several
oncogenes were later found. For example, c-sis oncogene which encodes
platelet-derived growth factor (PDGF), as well as oncogenes that encodes
constitutively active growth factor receptor tyrosine kinases (RTKs), for example,
v-erb for the epidermal growth factor receptor (EGFR) and non-receptor tyrosine
kinases, for example, ABL, that relay signals through the ubiquitous Raf/ MEK/
ERK pathway. 10

7

1.2.1 Receptor Tyrosine Kinase (RTK)
The membrane-spanning receptors of the RTK family constitute a ligandbinding domain, a single trans-membrane domain and an intracellular domain
with tyrosine kinase activity.11 The cytoplasmic domain contains a conserved PTK
domain that is subject to phosphorylation. A major requirement for signaling
mediated by RTKs is ligand-induced dimerization of receptors that result in the
autophosphorylation of the receptor subunits. These auto-phosphorylation sites
serve to recognize the src homology 2 (SH2) of a variety of signaling proteins.
One such protein is the adaptor growth factor receptor-bound protein 2 (Grb2).
The second binding domain of the adaptor molecule, SH3, allows it to associate
with the guanine nucleotide exchange factor (GEF), son-of-sevenless (SOS),
which catalyze GDP release and GTP binding which activates Ras.

12

As the first RTK to be discovered, the EFGR also known as ErbB1
homologous to the v-erb-B transforming protein of avian retrovirus is generally
used as a RTK model. The EGF signal is terminated primarily through
endocytosis of the receptor-ligand complex. There are various alterations that
interfere with ErbB receptors functions that contribute to human cancers.
Mutations are often found in the intracellular domain which affects tyrosine
kinase activity and abrogates the requirement for growth factor signals. In some
tumors, increased production of EGF-related growth factors leads to the
persistent activation of ErbB receptors. Similarly, over-expression of receptor,
and oligerimerization mimics of EFGR and other RTKs have been implicated in
numerous cancers including ovarian and gastric carcinomas and glioblastoma.

8
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1.2.2 Non-Receptor tyrosine kinase
The non-receptor kinases are key elements of intracellular signaling
induced by extracellular stimuli, such as cytokines and growth factors.These
proteins are localized both in the nucleus and cytoplasm, and regulate cell
growth, survival and morphogenesis via the PI3K/Akt and the Raf/MEK/ERK
pathways. The family of Abelson murine leukemia virus (c-Abl) tyrosine kinase
has gained much interest since the finding that a single molecular abnormality
can cause transformation of a hematopoietic progenitor into a malignant clone.
Similar to its receptor counterpart, c-Abl was originally identified as the cellular
homolog of the v-Abl oncogene of the Abelson murine leukemia virus, and its
function depends on its kinase activity, which is believed to involve
phosphorylation of Tyr245 and Tyr412. 14
Abnormality of the Abl protein through the reciprocal translocation
between the ABL chromosome 9 and chromosome 22 near a locus termed the
break-point cluster region (BCR) is the primary mode of deregulation in CML.
The result is a constitutively active ABL tyrosine kinase domain which abrogates
the need for activation by other cellular messaging proteins. This BCR-ABL
transcript, also called the Philadelphia chromosome (Ph+) accounts for more than
95% of hematopoeic malignancies. 15 Interestingly, in the stable or chronic phase
of CML while there is a massive increase in the number of white blood cells, their
maturation and function of the white blood cells are normal until a malignant
clone loses its ability to differentiate resulting in disease progression to highly
refractory leukemia.

9

1.2.3 Ras
Ras is a notable member of the GTPase superfamily (also known as
guanine nucleotide binding protreins), and it is a critical link that allows signal
transduction from the tyrosine kinases. Three isoforms have been identified (HRas, N-Ras and K-Ras). These proteins are typically anchored on the
cytoplasmic face of plasma membrane by farnesylation, where they cycle
between GTP-bound and GDP-bound state acting as a binary switch for several
signaling pathways including the Raf/MEK/ERK and the PI3K/Akt pathways. It
has been shown that there is specificity in the capability of isoforms to activate
the pathways; K-ras preferentially activates the Raf/MEK/ERK pathway whereas
K-Ras activates the PI3K/ Akt pathway.9
Localisation at the cell membrane allows the Ras proteins to be positively
regulated by guanine nucleotide exchange factor such as SOS which promotes
GDP dissociation. Consequently, the nucleotide free binding pocket will bind
GTP since its concentration in the cytosol is ten-folds higher than that of GDP,
markedly changing the conformation of the switch 1 and switch 2.

16

Figure  3: The sites of mutations detected in Ras are indicated. These mutations at (12,
13, 59, 61, 63) locks the Ras protein in an active state, which cannot be inactivated by
the GTPase.

10

Damage to these small GTPases switches can have catastrophic effects.
The Ras mutants are ranked among the most potent transforming proteins
known, accounting for 30% of all cancers, with pancreas (90%), thyroid (60%)
and colon cancer (50%) having the highest prevalence.

17

The activation of the

mutant Ras genes is invariably by point mutation at the codons: 12, 13, 59, 61
and 63 (Figure 3). 18,19 These activating mutations stabalize the GTP-bound state
and impair the GTPase activity of Ras, locking the Ras protein into its active
conformation. Within the ERK signaling pathway, active Ras binds the effector
Raf kinase, stimulating their translocation to the cell membrane, where Raf
activation takes place.

1.2.4 Raf
The Raf serine/ threonine kinases lie at the apex of the Raf/MEK/ERK
pathway module, and exist as the isoforms: A-Raf, B-Raf, and Raf1. These
proteins have three functional domains: CR1, CR2 and CR3 (Figure 4). The CR1
domain is necessary for Ras binding and activation. The CR2 domain is the
regulatory domain, and the CR3 is the kinase domain. Although these isoforms
share several structural features they exhibit non-redundant functions and differ
considerably in their modes of regulation.7,19
The recruitment to the cell membrane by GTP-bound Ras is the initiating
event and full activation of Raf-1 follows a complex sequence of (1)
phosphorylations/ dephosphorylations, (2) protein-protein interactions, and (3)
lipid/ protein interactions.

17

These events enhance the catalytic activity of Raf1

11

by both facilitating the activation of the kinase domain and neutralizing autoinhibitory molecules. The auto-inhibitory conformation state is maintained by 143-3 dimers, and relief from auto-inhibitory molecule entails dephosphorylation at
S259 by the serine threonine phosphatases (PP2A). This allows Raf-1 to assume
a new conformation in which it can be phosphorylated at S338, and activated by
kinases including P21 activated protein kinases (PAK).

20

The S259 and S338 sites of Raf-1 are conserved in A-Raf which follows a
similar activation patterns to Raf-1. However, B-Raf has two aspartate residues
at the position equivalent to S338 making the protein constitutively active due to
the negative charge of the aspartate. As a result B-Raf can be sufficiently
activated by Ras only, while Raf 1 requires other factors.

Figure  4: The sites of mutations detected in the B-Raf protein are presented. In all, 90%
of B-Raf mutations in melanoma involve V599. Mutations at S364, S428 and T439
insulate connectivity to the PI3K/ Akt pathway.

B- Raf is the most oncogenic isoform. B- Raf mutations have been reported in
66% of melanoma, 53 % of thyroid cancer and 30% of ovarian cancer.5 The
activating mutations within the kinase domain are the most aggressive, and often
converts Val599 to Glu. Interestingly, B-Raf mutations confer low kinase activity.
The recent discovery that B-Raf can form heterodimers with Raf-1 is a point of
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high interest. Recently, it has been shown that B-Raf can activate Raf-1. The
kinase activity of the B-Raf/ Raf-1 heterodimer is considerably higher than the
ability of either B-Raf or Raf-1 as independent entities. It is believed that
heterodimerization between B-Raf and Raf-1 proteins may allow the impaired BRaf to activate Raf-1. 21

1.2.5 Mitogen-activated Protein/Extracellular Signal-regulated Kinase (MEK)
MEK proteins are the most relevant target of Raf. This family of dualspecificity kinases has both S/T and Y kinase activity. Their structure constitutes
a regulatory domain and a MAP kinase-binding domain necessary for binding
and activation of ERKs. Surprisingly, there has been no identified oncogene
derived from MEK. MEK also differ from the upstream molecules Ras and Raf in
that it has relatively few phosphorylation sites.
0(.¶V DFWLYLW\ LV SRVLWLYHO\ UHJXODWHG E\ 5DI NLQDVH WKURXJK
phosphorylation at Ser 218 and serine 222.

21

MEK can be partially activated by

phosphorylation at either site. There are several featured MEK inhibitors that
block ERK activity by a noncompetitive mechanism, by binding in a pocket
adjacent to but not overlapping the ATP binding site. While this feature is
desirable, the demise of the MEK inhibitors is the high frequency of crosstalks
upstream MEK that can circumvents signaling beyond MEK.
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1.2.6 Extracellular signal-regulated kinases (ERK)
The main physiological substrates of MEK are the ERK family of serine/
threonine and tyrosine kinases of the Raf/MEK/ERK pathway, expressed in all
mammalian tissue, with ERK2 levels generally higher than ERK1.

Dual

phosphorylation activates both at T202/Y204 for ERK 1 and for T185/Y187 ERK2
in humans within a conserved Thr-Glu-Tyr (TEY) motif in their activation loop.  
Unlike MEK, ERK activation requires phosphorylation at both sites for full activity,
and Tyr phosphorylation has been shown to precede Thr phosphorylation. 22
Both nuclear and cytoplasmic have been identified for ERK. Activated Erk
can phosphoylate cytoplasmic signaling proteins including P90 ribosomal S6
kinase (RSK). ERK can also translocate to the nucleus, where it directly
phosphorylates member of the TCF family, for example Elk-1. TCF activate
numerous immediate early genes (IEG) including c-fos and c-myc that binds the
promoter of many genes. Accordingly, phosphorylation of TCF potentiates the
ability of IEG products to modulate the expression of many other genes including
cyclin D1; thereby, facilitating G1/S transition in the cell cycle. 4, 23
To date, over 160 substrates have identified.

24

The apparent specificity and

efficiency within the MAPK signaling is partly achieved through docking motifs,
namely, the D, DEF, CD, and ED domains which are present in scaffolding
proteins such as KSR. While the D domains are recognized generally by the
family of MAPKs, the second domain termed DEF (docking site for ERK and
FXFP), that consists of the Phe-Xaa-Phe-Pro sequence has been reported to be
recognized only by ERK1/2 in the C-terminal of the phosphoacceptor site. Also at
14

the C-terminal is the conserved common docking motif outside the catalytic
domain which contains acidic and hydrophobic residues necessary for
hydrophobic and electrostatic interaction with residues of the D-domain. Similar
to the D motif, the ED motif is adjacent the catalytic center of Erk which is also
believed to contribute to substrate binding specificity.

15
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1.3 The PI3K/Akt Pathway
Similar to ERK pathway, the engagement of several different growth
factors with RTKs feed into the PI3K/ AKT pathway. The net effect is the
inhibition of the apoptosis and stimulation cell cycle progression and cellular
translation. Germane to survival signaling the class 1a PI3K kinases triggers the
production of the second messenger phospatidylinisotol 3,4,5-triphosphate
(PIP3). PIP3 activates central engine of the pathway, AKT, which in turn
modulates several downstream signaling proteins (Figure 5). 20, 26, 27

Figure 5: Schematic diagram of the activation of the PI3K pathway and a number of
critical downstream targets.
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One of the most important AKT substrate is mTOR which allow the
pathway to mediate a key step in translational control. The classical thought was
that the pathway discretely exerts anti-apoptotic effects through phosphorylation
of critical targets including FOXO, BAD and caspases. However, recent studies
also indicate that Akt also promotes cell cycle progression by its ability to
phosphorylate MDM2 and GSK-3. Though, the connection between its role in
apoptosis and cell cycle is not entirely clear p53 seem to be involved.

1

Insult to the PI3K/ AKT pathway has been implicated tumorigenesis. The
importance of PI3Ks in cancer was confirmed by the discovery that the PI3K
catalytic subunit alpha-isRIRUP JHQH 3,.&$  ZKLFK HQFRGHV SĮ 2WKHU
defects in the pathway may include AKT are overexpression, and the negative
regulators of the pathway such as the tumor suppressor, PTEN may be mutated
or absent. 28,29

1.3.1 Phosphoinisitol Kinase (PI3K)
The PI3K proteins are a family of lipid kinases that serve to phosphorylate
the 3-hydroxy group of phospoinisitol. These PI3K proteins are cytoplasmic
heterodimers composed of a one of several p110 catalytic subunits, such as
PIK3Ca and PIK3Cb, and a regulatory p85 protein. The RTKs can activate the
PI3K pathways by two mechanisms. This may be directly through the binding of
the SH2 domain of p85 regulatory subunit of PI3K to specific phosphotyrosine
residue of the activated RTK.30 Alternatively, RTK may bind the adaptor proteins
which activate Ras inducible membrane translocation and activation of p110
17

catalytic unit of PI3K.31 The activated PI3K phosphorylates phoshatidylinositol3,4-bisphosphate (PIP2) to generate the secondary phoshatidylinositol-3,4,5triphosphate (PIP3). Subsequent signaling from the PI3k Ia is mediated primarily
through the recruitment of protein containing PH domain including PDK1 and
$.7WRWKH¶SKRVSKRLQRVLWLGHV The membrane bound phospholipid, PIP3, acts
as a docking site to bring the Akt from the cytosol to the plasma membrane in
closer proximity to (PDK1) poised for activation.
The contribution of PI3Ks to cancer progression was confirmed by the
discovery of the mutated PI3K catalytic subunit, alpha-isoform gene (PIK3CA),
which HQFRGHV SĮ 7KUHH RI WKH PRVW IUHTXHQW 3,.&$ PXWDWLRQV (.
E545K in the helical domain incur a charge reversal that inhibits electrostatic
interactions between the inserted amino acids and R340 and K379 on the SH2
GRPDLQRIUHJXODWRU\SĮ )LJXUH 6). H1047R in the kinase domain, have been
shown to increase PIP3 levels. It has been proposed that R forms a hydrogen
ERQG ZLWK / RI SĮ ZKLFK LQ WXUQ OHDGV WR FDWDO\WLF DFWLYLW\ RI SĮ

32

Cumulatively, studies indicate that the gain of function in helical domain
mutations is independent of binding to the regulatory p85 but requires binding to
RAS-GTP. In contrast, the kinase domain mutation is active in the absence of
RAS-GTP binding but is highly dependent on the interaction with p85. Colorectal,
brain and gastric cancers are reported to have a high rate of PIK3CA gene
mutation with frequencies of 32%, 27% and 25%, respectively.

18
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Figure 6: Mutations of the PIK3CA gene of the catalytic p110 domain in the helical
domain: E542K and E543 K, and in the catalytic domain H1047.

1.3.2 Akt
The AKT/ PKB serine/ threonine kinases are the principal target of the
PI3K pathway. Similiar to Ras, Akt was discovered as the cellular gene of the
transforming retrovirus AKT8 which exhibited kinase properties similar to protein
kinases A and C. It is expressed in three isoforms: Akt1, Akt2, and Akt3, all of
which possess an N-terminal pleckstrin homology (PH) domain involved in lipid
binding, a kinase domain and a regulatory C-terminal tail. Akt is activated via
phosphorylation of two residues: T308 and S473. 33 PIP3 facilitates the
phosphorylation of AKT at T308. An additional phosphorylation in the C-terminal
at S473 is also required for full activation, and the mammalian target of
Rapamycin 2 (mTOR 2) complex is believed to have some role, but the precise
mechanism remains controversial.
Activated Akt phosphorylates and stimulates many survival factors. It
promotes protein synthesis and growth by activating mTOR1 through effects on
the intermediary tuberous sclerosis (TSC) 1/2 complex. Akt influences apoptosis
by phosphorylating molecules such as BAD and BIM. Moreover, Akt can
modulate cell cycle progression via regulation of GSK-3 and MDM2 activity which
19

regulates cyclin D and myc.

1

A recent report identified a somatic mutation in the

PH domain of AKT1 (E17K) in 8% of breast cancers. The acidic Glu 17 typically
forms an ionic interaction with basic Lys 14 in the pocket however, in the case of
the Lys 17 substitution in E17K, the positively charged Lys 17 can no longer
interact

with Lys 14. Consequently, the mutated AKT1 product is recruited

to the membrane through a PI3K-independent mechanism. 1, 34

1.3.3 Mammalian Target of Rapamycin 2 (mTOR)
Integral to the translation of cell growth proteins in mammals is the murine
target of rapamycin mTOR, a multidomain serine/ threonine kinases known to be
inhibited by the drug rapamycin. As the downstream target of Akt, mTOR is
activated by Akt-induced phosphorylation of the intermediary tuberous sclerosis
complex2 (TSC2). The main function of mTOR is the regulation of translation,

particularly the recruitment of ribosomes to mRNA. Several survival proteins
SRVVHVVLQJDWHUWLDU\VWUXFWXUHZLWKSRO\S\ULPLGLQHVWUHWFKLQWKHLU¶XQWUDQVODWHG
region (UTR) are difficult to translate, and relies on mTOR for efficient translation.
7KLV UHTXLUHV WKH DVVHPEO\ RI D WUDQVODWLRQDO FRPSOH[ WKDW DWWDFKHV WR ¶ 875
The translation complex comprises eIF4E which recognize the cap structure at
WKH¶HQGRIP51$51$KHOLFDVHH,)$DQG its activator eIF4B which serves to
XQZLQG WKH ¶ 875 structure, all of which collaborates to allow the 40S ribosomal
subunit binding. 1,35

The activation of mTOR requires the association with Ras homologue
enriched in brain (Rheb) in its GTP form. The tuber schlerosis complex (TSC 1
/2) is the key integrator of PI3K/ mTOR signaling, and acts by promoting Rheb
20

GTPase activity which negatively regulate mTOR activation. However, TSC1/2 is
inhibited by PI3K signaling. The activated mTOR complex exerts its effect
through phosphorylation of ribosomal p70S6 kinase (S6K1) and the eukaryotic
initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1).

1

4E-BP1 is known to

LQKLELW¶FDS-dependent mRNA. The phosphorylation of 4E-BP1 releases eIf4E to
facilitate the mRNA binding to the rhibosome and translation initiation. The
phosphorylation of 4E-BP and the free eIf-4E generally stimulate two-fold
increase in translation. However the translation of specific protein such as c-myc
containing high structured UTR can be significantly larger. S6K1, in a more
indirect manner acts on many substrate including RNA helicase and other
substrates involved in translation. Both substrates stimulate the translation of
proteins necessary for cell growth and division of protein such as c-myc and
cyclin D. 35

1.3.4 Phosphatase and Tensin homolog deleted on chromosome 10 (PTEN)
The PI3K pathway is negatively regulated by the tumor suppressor protein
phosphatase and tensin homolog deleted on chromosome 10 (PTEN). The lipid
phosphatase serves to check and maintain balance between PIP2 and PIP3 by
degradation of PIP3 through the removal of the phosphate group from the 3'
position of the inositol ring. PTEN is ranked among the most common mutated
tumor suppressors in human cancers, second only to p53 mutations. The
immediate consequence of loss of function is increased levels of PIP3 and up
regulation of a number of AKT regulated proteins.

21
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1.4 The Raf/MEK/ERK, the PI3K/Akt Pathways and Apoptosis
The Raf/MEK/ERK cascade and the PI3K/Akt cascade have been
demonstrated to control the activity of several proteins involved in apoptosis. Of
the two modes of apoptotic regulation, designated as receptor mediated and the
mitochondrial mediated, the mitochondrial mode is thought to be the principal
target of survival signaling pathways. The Bcl-2 protein family is largely
responsible for this mode of regulation. The BH3-only members including Bad
and Bim, are essential initiators of apoptosis activated in response to distinct
cytotoxic and developemental signals. They selectively bind to pro-survival
members of the Bcl-2 family such as Bcl-2, Bcl-xL to trigger the mitochondrial
release of cytochrome c by a mechanism requiring their pro-apoptotic relatives
Bax or Bak (Figure 7). It is believed that the balance of the antiapoptotic proteins
and the pro-apoptotic proteins dictates cell survival or apoptosis.

13, 37

The BH3-only protein (B-Cell CLL/ lymphoma 2 (Bcl-2)/ Basal cell
lymphoma-extralarge (Bcl-xL) associated promoter (BAD) was the first proapoptotic Bcl-2 family member found to be regulated by extracellular survival
sinaling. In cells stimulated with mitogens, such as EGF, Bad is phosphorylated
at S136 by AKT. Several other reports indicate that RSK and S6K can both
phosphorylate BAD at S112.38 These phosphorylation events on apoptotic
regulatory molecules affect their stability, and alter their subcellular distribution.
Input from both pathways inhibits the pro-apoptotic activity of BAD by allowing
recognition by, and subsequent interaction with the 14-3-3 scaffold protein in the
cytosol. The BAD-14-3-3 heterodimer promotes cell survival by sequestration of
22

BAD in the cytosol where it is spatially separate from the mitochondria and proapoptotic members of the Bcl-2 family. Conversely, upon withdrawal of mitogens,
hypohosphorylated BAD induce oligerimerization of Bak and Bax. Activated
BAX/BAK dimer induces mitochondrial outer membrane permeabilization
(MOMP) release as cytochrome c from the mitochondrial intermembrane space
(IMS) to the cytosol where it binds protease-activating factor 1 (APAF1).
Thereby, forming a structure termed the apoptosome that recruits and activates
effector caspases such as caspase 9 which cleave and activate downstream
caspases, caspase 3 and 7, that participate in the execution of apoptosis. 37,39

Figure   7:   Interaction with Bad in the unphosphorylated state associates with Bcl-2 or
Bcl-XL to promote apoptosis. Akt and ERK phosphorylates Bad on S136 and S112
respectively. These phosphorylation events cause Bad to associate with 14-3-3 proteins,
thus inhibiting apoptosis.

23

A second BH3-only protein Bim, which has a major role in the death of
haematopoietic cells is also regulated by the two pathways. Akt can directly
phosphorylate Bim at S87 to promote binding to 14-3-3 proteins and inhibit its
proapoptotic activity. ERK phosphorylation of Bim on S69 can result in
ubiquitination of Bim and subsequent proteosomal degradation. In contrast to
BAD, Bim is also modulated at transcriptional level.

40

Reports indicate that the

pathways can cooperatively regulate the gene expression of Bim via the
transcription factor, Foxo-3a. AKT and SGK can phosphorylate FOXO3A at
Thr32, Ser253 and Ser315. Similar to post-transcriptional level, the 14-3-3
proteins bind the phosphorylated sites and sequester FOXOs in the cytosol,
thereby abrogating their ability to enter the nucleus and activate quiescent,
apoptotic genes expression. ERK phosphorylates FOXO3A at Ser294, Ser344
and Ser425, which increases FOXO3A interaction with the E3-ubiquitin ligase
MDM2, thereby directing proteasomal degradation of FOXO3a.
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The pathways also enhance the translation of several weak mRNA that
are often involved in apoptosis for example, Mcl-1. Such proteins possess tertiary
structures that are difficult to translate and require the assembly of a translation
FRPSOH[ZKLFKDWWDFKHVWRWKH¶8757KHWZRSDWKZD\VFRQWUROWKHDVVHPEO\RI
the eIF4E translation apparatus. ERK, p90 RSK1 and p70SK6 are a few
intermediatory molecules involved in the regulation of weak mRNA translation. In
some cases, the two pathways will phosphorylate the same molecule in the
translation complex such rhibosomal protein S6 (rpS6). 1, 40
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Recently it has been shown that the Raf/MEK/ERK cascade can
phosphorylate the terminal effector molecule, caspase 9 on residue T125 which
contributes to the inactivation of this protein.
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Interestingly, caspase 9 is also

phosphorylated by the Akt. The significance of the caspase 9 phosphorylation by
Akt is arguable, as this phosphorylation site is not evolutionally conserved.
However, cumulatively Raf/MEK/ERK and PI3K/Akt pathways appear to engage
in intimate crosstalk to regulate the survival status of dividing cells.
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1.5 The Raf/MEK/ERK, the PI3K/Akt Pathways and Cell Cycle
Cell cycle regulation is bi-modal requiring signal from both the Raf/MEK/
ERK and the PI3K/Akt pathways.
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In mammals, all cells with the exception of

liver and muscle rely on these pathways throughout their lifetime, for both
development, and maintenance and repair. In a normal cell, the cell cycle is an
orderly progression through four distinct phases Go/ G1, S, M, G2. In the S
(Synthesis) phase, the cell duplicates its DNA and in the M (Mitotic) phase, the
DNA is distributed equally between the two daughter cells. These two phases are
separated by the two gap phases Go/G1 and G2.
To ensure coordination, there is a restriction point at Go/G1 and two
additional checkpoints at the G1/S and G2/M. The core proteins involved in the
regulation of these checkpoints are the cyclins and the cyclins dependent
kinases.
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These cyclin/ cdk complexes are formed during the different phases.

The concentration of the cyclins are regulated by signaling, while the Cdks
concentration stays the same throughout the cell cycle and whilst their activity is
regulated in response to changes in cyclin concentration.
Present evidence indicates that CDK 4 and CDK 6 associate mainly with
cyclin D in the regulation of G1. CDK1 associate with cyclin B to regulate G2/M
transition, while CDK 2 is involved in the regulation of the G1/S transition and
DNA synthesis by its association with cyclin E and cyclin A (Figure 8).
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Cyclin D

is one of its most cited transcriptional targets of the relevant to cell cycle, a major
requirement for passage through the G1 restriction point and commitment to the
cell cycle. Sufficient accumulation of Myc is necessary for the activation of Cyclin
26

D expression, which subsequently associate with cyclin dependent kinases,
phosphorylate Rb, release E2F and promote DNA synthesis. 42,44

Figure  8: Erk and Akt stimulate cyclin D expression, and the association of cyclin D with
CDK causes phosphorylation of Rb. In the phosphorylated state Rb release the E2F
transcription factor promote DNA synthesis and progression through the phases.

The dynamic control of Myc by sequential phosphoylation allows Myc to
integrate upstream signals from Erk and AKT. It can be substantially stabilized
when phosphorylated at Ser62 by Erk activity. Subsequent phosphorylation of
Myc at Thr58 by Gsk3, however, initiates a destabilization process in a
sequential manner. Interestingly, phosphorylation at Thr58 requires prior
phosphorylation at Ser62.

38, 42, 45

Hence, as Ras activity declines, Gsk3b cease

the opportunity to initiates phosphorylation of Myc at Thr58 and triggers
degradation.
By inactivating GSK-B, PI3K pathway blocks Myc degradation. There has
been report of the pathways cooperatively increases cyclin D mRNA levels
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increase of up to 20 fold, which generally peaks after 6 hours of mitogen
stimulation.
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In addition to inducing the transcriptional activation of cyclin D1

and D2, Ras signaling also stimulate the phosphatase Cdc25A that removes the
negative regulatory phosphates from the Cdk. The myc transcription factor
functions as a heterodimer with its obligate counterpart Max. The related protein
Mad1 competes with Max. The myc/ max heterodimer positively regulate
transcription whereas the myc/ mad1 represses transcription. Studies also
indicate convergence of both pathways via RSK and S6K phosphorylate Mad1
on Ser 145. Thus, promoting Mad1 degradation, myc/max dimerization and
induction of growth genes not exclusive to cyclin D.
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Careful dissection has revealed that while sustained ERK1/2 activation is
required until the late G1 phase for successful entry into the S-phase, the
accumulation of PI3K products is necessary for the late G1 progression. 9
Evidence shows that the stimulation of quiescent cells (Go) cause two peaks of
activation. The first peak due to Raf/ MEK/ ERK activation and subsequent entry
into the G1, and the second at mid-G1 phase the PI3K pathway peak. Several
studies also suggest activation of the pathways in late S that persist until the end
of mitosis. Present evidence indicates that their mechanisms of regulation differ
during G2/M checkpoint. The inhibition of the PI3K pathway interferes with mitotic
entry by cdc25 activation and increase cyclin B1 expression, whereas inhibiting
the ERK pathway interferes with mitotic entry but has little effect on cdc25
activation and cyclin B1. 47
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1.6 Signaling Dynamics
The Raf/MEK/ERk and PI3K/Akt pathways are driven by phosphorylation
and de-phosphorylation reactions mediated by specific kinases, phosphatases,
adaptor proteins and scaffolding proteins. The balance between these signals
may widely vary in different tumors, and are important for sensitivity and outcome
of drug therapy. However, the protein kinases have rapidly become one of the
most pursued protein sub-family in the quest for novel drugs. Several compounds
have been credited with putative chemotherapeutic activity. The majority of these
inhibitors target various conformations of ATP, which often result in compounds
exhibiting multiple kinase targets. Besides, in 2001 Imatinib (Gleevec) became
the first therapeutic agent of a target molecule to enter clinical use. Imatinib acts
by blockade of the non-receptor tyrosine protein kinase BCR-ABL.48,49 Aberrant
signaling by these chimeric proteins is rather similar to signaling activated by
membrane bound receptor tyrosine kinase (RTK). The success of Gleevec has
been the long-standing proof of concept for targeting the Raf/MEK/ERK and the
PI3K/ Akt pathways.
The intrinsic mutations featured in the Raf/MEK/ERK are principally at Ras
and Raf.14 While several inhibitors have been developed to intercept oncogenic
signaling, the Raf and MEK inhibitors remain the most attractive target of the Raf/
MEK/ ERK pathway. To date, pluripotent Raf inhibitor, Sorafenib (BAY43-9006)
and the allosteric and highly selective MEK1/2 inhibitors, Sulumetenib (AZD6244)
and PD0325901 are the best explored inhibitors of the Raf/MEK/ERK pathway.
Sorafenib targets Raf, PDGFR and VEGFR, and was approved for the treatment
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of advanced renal cancer.50,51 CI-1040, the first MEK inhibitor to enter clinical
trials, and its second generation inhibitors PD0325901 were well tolerated by
patients

but

showed

insufficient

anti-tumor

activity

to

warrant

further

developement. Similiarly, a second MEK inhibitor AZD6244 was terminated as a
mono-therapy drug candidate in late phase trials in patients with melanoma, and
it is currently in clinical trials for combination therapy. 52
As for the PI3K/Akt pathway, mutations are most frequently reported at
Akt, PTEN and PI3K. Within the PI3K/PTEN/Akt pathway, the main therapeutic
targets: PI3K, mTOR and Akt (also referred to as PKB). In the PI3K pathway the
second generation rapamycin analogs with improved pharmacological properties
show productive therapeutic outcomes. The best evidence is the treatment of
advanced renal cancer with tersirolimus, a rapamycin prodrug that has been FDA
approved. 53 Others include the water soluble rapamycin (CCI-779) in phase III of
development, and the two other agents, (RAD001) and (AP23573) in earlier
phases of development. The PI3K inhibitors have been less successful.
LY294002 and wortmannin, two well-known PI3K inhibitors, were shown to have
effective anti-tumor activity, but had limited clinical value due to poor
pharmacokinetic properties.
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Likewise, perifosine, the most developed AKT

inhibitor has not been shown to be beneficial as a single agent in several phase II
studies.
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Regardless, the repertoire of well-characterized inhibitors should not

be discounted based on grim rate of success, as they have contributed a wealth
of information to targeted cancer research.
While the small molecules inhibitors of the pathways are forecasted to
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significantly impact the cancer chemotherapy, the underlying biochemical
complexity remains a challenge. There exist several different layers of regulation
which is heavily dependent on cell type, dosage and duration. Supporting studies
indicate distinct differences in cell lines from same target tissue, although results
from some in-vitro reports suggest similar mechanism from cell of differing origin.
In a study by Kiyatkin this phenomenon was highlighted with MCF7 and T47D
breast cancer cell lines. The T47D breast cancer cells displayed MEK resistance
due to a PI3K/ AKT sensitive compensatory pathway, which was absent in the
MCF7 breast cancer cell line which appear to signal predominantly through the
MAPK pathway.56
There are also examples of dependence on dose and duration. In an
elegant study by Haugh, ERK and PI3K -dependet Akt phosphorylation in PDGFstimulated NIH 3T3 fibroblasts were evaluated using different combinations of
ligand dose and stimulation time. The results supported the notion that the extent
of ERK inhibition depends strongly on both dose and duration. At short
stimulation time, ERK activation was substantially effected by PI3K inhibition
when stimulated by low but not high PDGF concentration. The effect of Ras
inhibition was similar but ERK phosphorylation was less sensitive to PDGF
concentration.
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The observed stimulation conditions are believed to be subject

to negative feedback loops, but a definitive pattern is yet to emerge.
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2.  Crosstalk  of  the  Raf/MEK/ERK  and  PI3K/Akt  Signaling  Pathways  
The cosstalk between the two pathways is undisputed, and suggest high
intimacy between the regulation of cell cycle and apoptosis (Figure 9). The
transcription factors, Myc and E2F exist at the core of this interface. Myc
activates E2F which promotes the transition of phase G1 to S the cell cycle.
58

Overexpression of E2F stimulates the expression of tumor suppressor, ARF,

which inhibits the activity of MDM2. It is believed that the MDM2, an E3 ubiquitin
ligase, targets p53 and accelerates its proteolytic degradation and maintains p53
at a low level.
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Thus, by inhibiting MDM2, ARF prevents p53 degradation and

consequent stabilization. This would result in either p53 dependent apoptosis or
cell cycle arrest due to p53 blockade.

Figure   9. Simplified representation of the crosstalk between Erk and Akt; and the cell
cycle and apoptosis.
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   A direct consequence of the crosstalk is the generally disappointing

single-targeted therapy against the different components developed based on
traditional understanding of the means by which these pathways were thought to
govern cell processes. The pathways were characterized as simple, linear and
unidirectional. However, emerging studies have revealed that the two seldom act
in isolation, but rather through multiple crosstalk and feedback interaction within
a complex, well-coordinated network (Figure10).38 As such, it is apparent that
perturbations targeting specific signaling molecules may have unexpected
effects, and in some cases the compensatory pathways have been shown to
mediate drug resistance.59 In view of this, a great deal of effort has been focused
on experiments aimed at improving the understanding of the interplay and
molecular mechanisms of the two pathways, which will in turn provides access to
novel strategies with improved clinical outcome.
Encouragingly, several studies indicate that simultaneous inhibition of the
pathways may be required for optimal efficacy. Theoretically, the complete
blockage of the pathways at upstream receptors may be valid, but could have
deleterious effects and may result in significant normal cell toxicity. Alternatively,
blocking a subset of downstream effector molecules would be a more pragmatic
approach.

Interestingly,

there

have

been

collaborations between

large

SKDUPDFHXWLFDO FRPSDQLHV )RU H[DPSOH WKH FRPELQDWLRQ RI 1RYDUWLV¶ 3,.
LQKLELWRU %.0  DQG *6.¶V 0(. LQKLELWRU *6.  LQ SKDVH ,
development for triple negative breast cancer. Similarly, the combination of
$VWUD=HQHFD¶V 0(. LQKLELWRU $='  DQG 0HUFN¶V $NW LQKLELWRU 0. 
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undergoing phase I trials for locally advanced or metastatic solid tumors.26
Evidently, a single compound targeting both pathways is a realistic therapeutic
option with inherent advantages of increased patient compliance and reduced
risk of drug resistance.
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3. Rationale: Discovery and identification of lead dual-pathway inhibitor of
the Raf/MEK/ERK and PI3K/AKT signaling pathways.
3.1 Development of ERK1/2 inhibitor. ERK1/2 represents a near optimal target
to develop such inhibitors given the following facts: (1) the important position of
ERK1/2 in the Raf/MEK/ERK1/2 pathway that controls the distribution of signals
from upstream; (2) the disclosure of the crystal structures of ERK2; and (3) The
identification of the docking groove composed of a common docking (CD)
domain and an ED domain on ERK2 and the validation of their roles in the
control of docking interaction with substrate proteins. Taking advantage of a
IDYRUDEOH VLWXDWLRQ WKH 6KDSLUR¶V JURXS LGHQWLILHG VHYHUDO VXFK LQKLELWRUV E\
computer-aided virtual screening of a small library of compounds (Fig. 10).60

Figure 10: Putative substrate-specific ERK 1/ 2 inhibitors

Among these structures, compound 76 represents an interesting chemical
scaffold. Compound 76 inhibited the phosphorylation of the downstream
substrate of ERK1/2, Rsk and Elk-1, in U937 cells with minimal effects on the
phosphorylation of ERK1/2. In addition, small molecules containing the
35

thiazolidine-2,4-dione moiety, such as the anti-diabetic drug troglitazone, have
been recently reported to have anti-cancer activities. Thus, these results
demonstrated the potential of compound 76 as a new chemotype to develop
substrate-specific ERK1/2 inhibitors. 60
Due to the fact that compound 76 was discovered as a lead through
screening, little information about the pharmacophore of compound 76 is known
and there have been no reports of efforts to modify 76 to improve its bioactivity.
In a previous study, we initiated preliminary structure-activity relationship (SAR)
studies of compound 76 to define its pharmacophore and to search for more
potent and selective substrate-specific ERK1/2 inhibitors. Immunoblot studies
established that 1c showed improved activity compared to 76 (Fig. 13A). 61
C

76
D

1c
Figure 13: Effect of test compound on Rsk, ERK 1/2, Elk-1, MEK 1/2 and p38
phosphorylation. A: Immunoblot results B: Quantification of Rsk-1 phosphorylation by
densitometry C: Compound 76 and D: Compound 1c.
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3.2 Discovery of a lead dual-pathway inhibitor. In our effort to design and
discover novel templates targeting the Raf/MEK/ERK and the PI3K/AKT signaling
cascade, we have embarked on further characterization of our recently
discovered lead ERK inhibitor, 1c. Preliminary structure±activity relationship
(SAR) studies was initiated to define its pharmacophore. To facilitate the
structure activity relationship the lead was again divided into three domains: a
phenyl ring domain, a thiazolidinedione domain and an ethylamine domain.
Compound 1 emerged as a novel chemotype with several features that may have
contributed to its activity. These include the phenylpropylidene double bond as a
Michael addition acceptor, the primary amine for ionic interaction and the
aromatic ring for hydrophobic interaction.63
The cell viability and proliferation effect of compound 1 was investigated
using the [(3- (4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] (MTS) assay and 3H thymidine respectively in U937
cells. The known MEK inhibitor PD184352 was used as positive control.
Compound 1 exhibited significant inhibition on U937 cell viability at higher
concentrations (15, 20, and 25 PM) but not at concentration less than 10 PM
(Figure 13C). Since the MTS assay only examines the metabolically healthy
cells, but cannot distinguish whether the cells are actively dividing or quiescent,
the [3H]- thymidine incorporation assay was used to investigate the actively
dividing cells by detection of DNA synthesis. At 10 PM, 1 significantly inhibited
the [3H]-thymidine incorporation, while PD184352 did not. At 30 PM, 1 almost
completely inhibited [3H]-thymidine incorporation, and PD184352 also exhibited
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significant inhibition at this concentration (Figure 13D). Taken together, these
results may indicate that 1 may induce early apoptosis of U937 cells through
inhibiting DNA synthesis at 10 PM but not affecting cell viability.
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Figure  14.  Western blot analysis of compound 1 and its analogs in U937 cells a) Raf/
MEK/ ERK components b) PI3K components. Inhibition of cell proliferation using MTS
assay (c) and [3H]-thymidine incorporation (d) in human leukemia U937 cells.

To get insight into the signaling pathways that DUHSRVVLEO\LQYROYHGLQ¶V
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functional activities, Western blot analysis was then performed in U937 cells. As
shown in Figure 14A, PD184352 significantly inhibited the phosphorylation of
both ERK and its downstream substrate Rsk1 at as low as 3PM concentration.
Compound 1 also significantly inhibited the phosphorylation of ERK and Rsk1 at
10 PM and 30 PM concentrations, therefore being slightly less potent than
PD184352 (Figure 14). However, when the p-MEK level was evaluated, it is
notable that 1 induced dose dependent decrease the p-MEK level in U937 cells
while treatment with PD184352 resulted in a dose-dependent increase in the pMEK levels, which is consistent with the reported negative feedback mechanism
in the Raf/MEK/ERK pathway. Interestingly, 1 at 25 PM significantly suppressed
p-Akt levels while the specific MEK inhibitor showed no inhibitory effects. This
might indicate that 1 targets either an upstream activator of MEK in the
Raf/MEK/ERK signaling pathway or it inhibits MEK via a different mechanism.
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4. Objective: Development of oxindole analogs as potential dual pathway
inhibitors and anticancer agents. In order to develop novel chemotype of
dual-pathway inhibitors as well as to develop a chemical template that would
provide more flexibility for future structural modification, we intend to replace the
TZD ring with an oxindole ring (Figure 15). The oxindole was identified as a
more attractive replacement for the thiazolidinedione ring based on parallel
study with the maleimide analog using the MTT assay. The design hypothesis
was that both ring system would orient the critical structural features such as the
ring system, the spacer and the ethylamine tail in a similar manner to that in the
TZD analogs, and thereby retain the biological activity as dual-pathway inhibitors
of the Raf/MEK/ERK and PI3K/Akt signaling pathways.
In comparison to the thiazolidinedione lead, the oxindole analog showed
improved potency (4-fold increase) while the maleimide analog showed a
decrease in potency (10-fold decrease). This suggests that the aromatic ring
system of the oxindole ring which is absent in the maleimide ring may contribute
to the observed activity. The results were also consistent with the recognition of
the oxindole template as a privileged template in drug discovery. In addition to
the oxindole analog being 4-fold more potent than the lead compound 1, the
oxindole ring would also provide greater flexibility to allow the introduction of
various substituents, and thus facilitate comprehensive SAR studies for future
investigation.
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Figure 15: Thiazolidinedione lead and designed oxindole analogs.
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4.1 Design of oxindole analogues. To obtain structural information about the
features of compound 2 that are critical to the anticancer activity, compound 2
was divided into the said three domains like compound 1, namely (1) phenyl ring
domain; (2) ethylamine domain and (3) oxindole domain. As shown in figure 15,
compounds 2-6 were designed to highlight the role of the aromatic ring in
biological activity. Particularly, it was examined if the replacement of the phenyl
ring with cyclohexyl, adamantyl, cyclopropyl or nonyl groups would be tolerated
or improve activity. Compounds 7-13 were designed to evaluate the influence of
electrostatic and sterics of the substituent on the phenyl ring on the biological
activity. The substitutions were made in 4-phenyl position and varied from high to
moderate electron-donating and electron-withdrawing groups (Figure 15).
The synthesis was initiated with the preparation of various aldehydes as
shown in Scheme 1. The substituted benzaldehydes were converted to their
Meldrum¶s acid derivatives followed by reduction and hydrosilylation to give the
different aldehydes.
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Scheme 1: a) Meldrum acid, piperidine, EtOH b) NaBH4, AcOH, CH2Cl2; c). PhSiH3,
Et3N, THF c) DMSO, (COCl)2, Et3N, CH2Cl2, -78oC

The synthesis 3-cyclohexylpropanal, 3-cyclopropylpropanal as well as 3adamantan-1-yl)propanal was achieved through the oxidation. While (3cyclohexylpropanal and 3-cyclopropylpropanol were commercial available, 3-
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adamantan-1-yl)propanal required synthesis. As shown in scheme 2, this
synthesis started with the radical conjugate addition of bromoadamantane 25 to
ethyl acrylate using nBu3SnH to afford the adamantyl ester 26. Reduction with
lithium aluminum hydride (LAH) then yielded the primary alcohol 27. 3cyclohexylpropanol, 3-cyclopropylpropanol as well as 3-adamantan-1-yl)propanol
were subsequently obtained by swern oxidation

Scheme 2: a) nBu3SnH, AIBN, ethyl acrylate, toluene, rt b) LAH, THF, rt c) DMSO,
ClCH2OCl, Et3N, CH2Cl2, -78oC
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Scheme 3: a) DMSO, ClCH2OCl, Et3N, CH2Cl2, -78oC

In retrospect, compound 36 was synthesized in a four-step reaction
beginning with aniline. The N-substituted Boc analog of aniline was synthesized
from the alkylation reactions with 2-bromoethylamine and carbamic acid tert-butyl
ester. The secondary amine of compound of compound 34 was readily
acetylated to the chloroacetanilide. With catalytic amounts of palladium acetate in
combination with 2-(di-tert-butylphosphino)biphenyl as a ligand, and triethylamine
as base, the chloroacetanilides was converted to oxindoles with high levels of
regioselectivity. Knoevenagel condensation of the various aldehyde with
compound 36, followed by the removal of Boc or tert-butyl ester group afforded
compounds 2-13 (scheme 4).
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Scheme 4: a) H2NCH2CH2Br, toluene, reflux; b) Boc2O, MeOH, rt c) ClCH2OCl, CH2Cl2,
0oC, d) Pd(OAc)2, L, Et3N, toluene, 80oC e) RCHO, piperidine, EtOH, reflux (f) DioxaneHCl, EtOAc

The scheme employed to synthesized the oxindole analogues was
carefully devised. As a starting material, aniline has the advantage of being
cheap and available. Another favorable feature of this synthetic route is the
palladium catalyzed C-H functionalization. This step circumvent the need for high
temperature as in the Wolff-Kishner reduction of isatin to oxindole, as well as the
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combination of both high temperature and strongly acidic in Friedel-craft
reasction.

Abrogating the need for harsh conditions, the palladium-catalysed

synthesis of oxindole cyclization is highly compatible extending to even electron
difficient aromatic systems.
The maleimide analog 43 in the preliminary set of experiment was also
synthesized. The condensation of the maleimide and hydrocinnamaldehyde was
achieved by Wittig reaction through a phosphorane intermediate 40. The Nalkylated product 42 was obtained by Mitsonubu reaction.

Scheme   5: (a) PPh3, acetone, reflux; (b) RCHO,
BocNHCH2CH2OH, PPh3, DIAD; (d) Dioxane-HCl, EtOAc.
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methanol,

reflux;

(c)

3. Discussion
3.1 Anti-proliferative activity in human leukemia U937 cells. The activation of
the Raf/MEK/ERK and PI3K/Akt signaling pathways has been shown to play
multiple roles in the cell proliferation and apoptosis of hematopoietic cells
including U937 cells. Accordingly, the U937 cells were employed for preliminary
testing of the compounds. We first tested the anti-proliferative activity of the
designed oxindole analogs. Notably, as shown in Table 1, all of the designed
compounds exhibited anti-proliferative activity against the growth of U937 cells
with micromolar or sub-micromolar potency. This also confirms that oxindole
template can retain the anti-proliferative activity of these analogs, thus supporting
our design rationale.
Compared to lead compound 1, compound 2 in the oxindole series
improved anti-proliferation activity (4-fold increase). While the cyclohexyl analog
exhibited improved antiproliferation activity in comparison to compound 2, in the
oxindole series, compound 3 exhibited comparable effects to compound 2,
suggesting that sterics may not play a pivotal role since the phenyl ring is planar
whereas the cyclohexyl group can flip between the chain, boat and other
translational conformations. This notion was further supported by the fact that 4
and 5 with the cyclopropyl ring and the adamantyl ring respectively showed
comparable anti-proliferation potency with compound 2.
Compounds 7 and 8 exhibited anti-proliferative activity with sub micromolar potency, the best two among the compound tested here. Combining the
results from compound 2-6, this may indicate that the target protein may contain
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a narrow binding pocket to interact with phenyl group through hydrophobic
interactions. This hypothesis was further supported by the results of compounds
9 and 10 with reduced potency in comparison to 7 and 8. As compound with
electron-withdrawing substitutions on the phenyl ring (compounds 11-14) they
also exhibited comparable potency to compound 2, suggesting mainly
hydrophobic interactions with the phenyl ring. Interestingly, variation of the
inhibitory effect on the U937 was most evident at 3 PM of drug concentration,
which is around the average IC50 value for the series (Figure 17). Notably,
compound 7 was observed to significantly inhibit cell growth at 3 PM (73.5 %
inhibition) while other compounds achieved the same inhibition at 10 PM.

Figure 16: U937 cells were treated with compounds 2-13for 72 hours and the viability
was analysed using the MTT assay
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Table 1: Growth inhibition of U937 cells by compounds 2-13 (PM)

A  

B  

  
C  

  

D  

  
  
Figure 17: Anti-proliferative effects of compounds on U937 cells assayed using MTT.
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3.2 Western Blot Analysis of compounds 7 and 10. To confirm that the growth
inhibition of U937 cells by these oxindole analogs were mediated through the
inhibition of the Raf/MEK/ERK and PI3K/Akt signaling cascades. Compounds 7
and 10 were selected for western blot analysis in U937 cells, as compound 7 was
the most active one among the tested analogs and its comparison with
compound 10 may shed some light on mechanistic information.

Figure   18: U937 cells were treated with Compound 7 and 10 at the indicated
concentrations for 24 hours. Lysate from culture was analyzed by primary antibodies.

As shown in Figure 18, both compounds consistently suppressed the
expression of the critical components of these two signaling pathways, p-ERK
and p-AKT, at concentration as low as 5 PM. Surprisingly, compound 10
appeared to have a more significant effect on inhibition of p-ERK than compound
7, while compound 7 is more potent than compound 10 in the anti-proliferation
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assay of U937 cells. This may indicate that a more balanced inhibition on both
signaling pathway is necessary to show optimal pharmacological outcome. As
reflected by anti-proliferation here, the significant inhibition of one signaling
pathway does not equal to the optimal cytotoxic effects, thus, further attesting to
the rationale of designing dual-pathway inhibitors. Taken together, the results of
the anti-proliferative assay and western blot indicate that signaling blockage and
growth inhibition by these newly designed oxindole analogs in U937 cells are
correlated.

3.3 Apoptotic effects of compounds 7 and 10. As the Raf/MEK/ERK and
PI3K/Akt signaling pathways have been demonstrated to play important roles in
regulating apoptosis, the apoptotic effects of 7 and 10 were evaluated in U937
cells using cytometry to obtain preliminary mechanistic data for the antiproliferative activity. As shown in Figure 19, both compounds significantly
induced apoptotic effects on U937 cells after 24 hr treatment at as low as 5 M
(63.9% and 21.7% for compound 7 and compound 10, respectively).
Both

compounds also

induced

significant

apoptosis

at

10

PM.

Interestingly, compound 7 induced early apoptosis at both concentrations while
compound 10 only induced late apoptotic effects in U937 cells under the
experimental conditions. As discussed above, compound 7 and compound 10
have different inhibitory effects on the Raf/MEK/ERK and PI3K/Akt signaling
pathways as demonstrated by western blot results. This phenomenon might
contribute to the distinct apoptotic effects since both signaling pathways can
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regulate apoptosis through differential downstream substrates. This also does
not rule out the possibility of the involvement of other off-targets that these two
compounds might interact. Further studies are needed to get more information
about the mechanism underlying the different apoptotic effects in U937 cells.

Figure  19: Compounds 7 and 10 induced apoptosis in U937 cells. The U937 cells were
treated for 24 hours with the drugs, after which they were stained with Annexin VI/ PI
and analyzed by flow cytometry.
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3.4 Conclusion In summary, the work presents the design and biological
characterization of a series of oxindole compounds as novel dual-pathway
inhibitors of the Raf/MEK/ERK and PI3K/AKT pathways. The MTT antiproliferative assay, western assay and apoptotic assay were employed to
investigate biological activity in human leukemia U937 cells. All of the designed
compounds exhibited anti-proliferative activity against the growth of U937 cells
with micromolar or sub-micromolar potency. Western blot analysis correlated the
anti-proliferative activity of the Raf/MEK/ERK and PI3K/Akt signaling pathways
with suppression of critical pathway components. Lastly, the apoptotic assay
shed some light one the preliminary mechanistic information. Taken together the
results strongly support our design rationale by showing anti-proliferation,
inhibitory effects of the signaling pathways, and apoptotic effects of these
oxindole analogs. The results also suggest the potential of the oxindole template
as new lead compounds to develop newer generation of dual-pathway inhibitors
of the Raf/MEK/ERK and PI3K/Akt.
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5. Experimental
*HQHUDO3URFHGXUHIRU3UHSDUDWLRQRIPHOGUXP¶VDFLGLQWHUPHGLDWHV : To a solution
RI0HOGUXP¶VDFLG PPRO DQGGURSVRISLSHULGLQHLQHWKDQRODU\ODOGHK\GH
was added. The resulting solution was stirred at room temperature overnight.
The reaction mixture was filtered via Buckner filtration and washed with ethanol
and methanol to obtain the pure intermediate.
5-(3-(4-Methoxyphenyl)-methylene)-2,2-dimethyl-1,3-dioxane- 4,6-dione (15)
1

H NMR (300 MHz, CDCl3): 8.38 (s, 1H), 8.24-8.21 (d, J= 9.3 Hz, 2H), 6.99-6.97
(d, J = 9.3 Hz, 2H), 3.91 (s, 3H), 1.79 (s, 6H).
5-(3-(4-Ethoxyphenyl)-methylene)-2,2-dimethyl-1,3-dioxane- 4,6-dione (16)
1

H NMR (300 MHz, CDCl3): 8.37 (s, 1H), 8.23 (d, J = 9.3 Hz, 2H), 6.97-6.996.55 (d, J = 9.3 Hz, 2H), 4.13-4.08 (q, J = 7.0 Hz, 2H), 1.78 (s, 6H), 1.26-1.23, (t,
J=6.9Hz, 3H).
5-(3-(4-Butoxyphenyl)-methylene)-2,2-dimethyl-1,3-dioxane- 4,6-dione (17)
1

H NMR (300 MHz, CDCl3): 8.37 (s, 1H), 8.22-8.21 (d, J = 9.3 Hz, 2H),6.97-6.95
(d, J = 9.3 Hz, 2H), 4.09-4.06 (q, J =7.0 Hz, 2H), 1.78 (s, 6H), 1.55-1.45 (m, 2H),
1.01-0.97 (t, J=7.4 Hz, 3H)
5-(3-(4-Chlorophenyl)-methylene)-2,2-dimethyl-1,3- dioxane-4,6-dione (19)
1

H NMR (400 MHz, CDCl3): d 8.37 (s, 1H), 8.04-8.02 (d, J = 8.7 Hz, 2H), 7.477.45 (d, J =8.7 Hz, 2H), 1.81 (s, 6H).
5-(3-(4-Florophenyl)-methylene)-2,2-dimethyl-1,3- dioxane-4,6-dione (20)
1

H NMR (400 MHz, CDCl3): 8.39 (s, 1H), 8.19-8.15 (m, 2H), 7.17 (t, J=8.5 Hz,
2H), 1.80 (s, 6H)
5-(3-(4-Nitrophenyl)-methylene)-2,2-dimethyl-1,3-dioxane-4,6- dione (21)
1

H NMR (300 MHz, CDCl3): d 8.46 (s, 1H), 8.32-8.29 (d, J = 9.3 Hz, 2H),
8.08.08-8.05 (d, J = 9.3 Hz, 2H), 1.84 (s, 6H).
To a solution of 5-DU\OLGHQH0HOGUXP¶VDFLGGHULYDWLYH PPRO DQGJODFLDODFHWLF
acid (4 mL) in dichloromethane at 0oC was added sodium borohydride (3.2 mmol)
dropwise. The solution was dissolved in dichloromethane and washed with brine
and water. The organic phase was extracted, dried over NaSO 4. The monoakyl
meldrum acid derivative (1 mmol) was dissolved in THF. Triethylamine (2 mmol)
was then added followed by phenysilane (3 mmol). The resulting solution was
stirred for 2 hrs at room temperature. Water was added to the solution and stirred
for 15 mins. The reaction was dissolved in ether (50 mL) and washed with water
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(2X50 mL) then with brine (50 mL). The organic layer was extracted. The
separated ether phase was washed with brine and purified by flash
chromatography (Hexane/ethyl acetate (EtOAc) 10/1) to give a colorless oil.
5-(4-butoxybenzylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione (22)
1

H NMR (300 MHz, CDCl3): 8.37 (s, 1H), 8.23-8.21 (d, J=8.96, 2H), 6.97-6.95 (d,
J=9.0 Hz, 2H), 4.09-4.06 (t, J=6.48 Hz, 2 H), 1.78 (s, 6H), 1.55-1.49 (q, J=7.2 Hz,
2 H), 1.01-0.97 (t, J=7.4, 3 H), 1.76-1.74 (d, J=7.0 Hz, 2 H), 1.72 (s, 3H), 1.501.44 (m, 5H)  
5-(4-butoxybenzyl)-2,2-dimethyl-1,3-dioxane-4,6-dione (23)
1

H NMR (300 MHz, CDCl3): 7.23-7.21 (d, J=8.64 Hz, 2H), 6.81-6.79 (d, J=8.64),
3.93-3.90 (t, J=6.52 Hz, 2H), 3.73-3.70 (t, J=4.84 Hz, 1H), 3.44-3.42 (d, J=4.84
Hz, 2H)
3-butoxy-propionaldehyde (24)  
1

H NMR (400 MHz, CDCl3): 9.81 (s,1 H), 7.10-7.08 (d, J=8.6 Hz), 6.83-6.81 (d,
J=8.6 Hz, 2H), 3.95-3.92 (t, J=6.52, 2H), 2.92-2.88 (t, J=7.48, 2H), 2.76-2.72 (t,
J=8.44, 2H), 1.77-1.71 (q, J=7.12 Hz, 2H), 1.55-1.43 (m, 3H), 0.99-0.95 (t, J=7.4
Hz, 3H)  
DMSO (14.0 mmol) was added dropwise to a stirred solution of oxalyl chloride
(5.0 mmol) in DCM (20.0 mL) at 78 C and the resulting reaction mixture was
stirred for 20 min at this temperature. Then cyclopropyl-propanol or cyclopropylpropanol (4.0 mmol) was added dropwise and stirred for 1 h followed by the
addition of Et3N (1.0 mL). The reaction was gradually brought to room
temperature and H2O was added. The separated DCM phase was washed with
brine and purified by flash chromatography (Hexane/ 1007
ethyl
acetate
(EtOAc): 10/1) to give a colorless oil.
3-Cyclopropyl-propionaldehyde (31 a)
1

H NMR (400 MHz, CDCl3): d 9.80 (t, J = 1.8 Hz, 1H), 2.55-2.51 (m, 2H), 1.571.51 (m, 2H), 0.71-0.67 (m, 1H), 0.48e0.43 (m, 2H), 0.07-0.04 (m, 2H).
3-Cyclohexyl-propionaldehyde (31 b)
1

H NMR (400 MHz, CDCl3): d 9.77-9.76 (t, J = 1.9 Hz, 1H), 1011 2.45-2.41 (t, J
= 7.5, 1.9 Hz, 2H), 1.71-1.55 (m, 5H), 1.51-1.49 (m, 2H), 1.26-1.11 (m, 4H), 0.930.86 (m, 2H).
Maleimide (1 mmol) and triphenylphosphine (1 mmol) in acetone (10 mL) was
refluxed for 1 hour. The formed precipitates were collected by sucking filtration
and washed with acetone. Yield, 65%.
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3-(3-phenylpropylidene)pyrrolidine-2,5-dione (40)
1

H-NMR(400 MHz, CDCl3): į 7.63- 7.52 (m, 15 H), 3.03 (s, 2 H), 1.6536 (s, 2 H)

Aromatic aldehyde (1 mmol), triphenylphosphoranylidene succinimide (1 mmol)
and methanol were added a flask. The reaction mixture was stirred at reflux
temperature for 1.5 hours. Yield, 45%.
1
3-(3-phenylpropylidene)pyrrolidine-2,5-dione
(41):
H-NMR(400
MHz,
CDCl3)į-7.15 (m, 5H), 6.86-6.81 (m, 1H), 3.01 (s, 2H), 2.83-2.80 (t, J=7.36,
2H), 2.52-2.47 (q, J=7.44, 2H)

A toluene solution of the Mitsonobu reagent, DIAD (1.5 mmol), was added
dropwise to a THF solution of triphenylphosphine (1.5 mmol), maleimide
derivative (1 mmol) and 2-tert-butoxycarbonylaminoethanol at room temperature.
The reaction was stirred overnight. Solvent was removed under pressure and
pure product was obtained by column chromatography. The Boc-protected
compound (1 mmol) was dissolved in ethylacetate (3 mL). Dioxane-HCl (1
mmol) was added to the flask and the reaction was stirred for 2 hrs. Solid
suspension was observed, the mixture was filtered and the collected solid
washed with ethyl acetate and ether.Yield, 72%.
(2-(2,5-dioxo-3-(3-phenylpropylidene)pyrrolidin-1-yl)ethanaminium chloride
(43)
1

H-NMR(400 MHz, MeOD): į -7.17 (m, 5H), 6.83-6.78 (t, J=6.6 Hz, 1H),
3.85-3.81 (t, J=7.6 Hz, 2H), 3.183-3.130 (m, 4H), 2.86- 2.81 (t, J=7.5, 2H), 2.602.53 (q, J=7.8 Hz, 2H).
Preparation of N-alkylated oxindole:   A mixture of 2-bromoethylamine
hydrobromide (0.1 mmol) and analine (0.2 mmol) in 40 mL of toluene was heated
at reflux for 16 hrs and then cooled. A solution of 60 mL of water and 20 mL of
50% aqueous KOH was added, and the layers were separated. The aqueous
solution was saturated with NaCl and extracted thrice with dichloromethane. The
combined organic layers were washed with saturated NaCl solution, dried over
anhydrous Na2SO4, filtered and evaporated to dryness. Column chromatography
gave the pure product. Yield, 60%.   
N1-phenylethane-1,2-diamine (33):
1

+ 0+]0H2+ į-7.08 (t, J=3.4 Hz, 2H), 6.67-6.60 (m, 3H), 3.23-3.20
(t, J= 6.08 Hz, 2H), 2.90-2.87 (t, J=6.24 Hz, 2H).
A solution of N-phenylethylenediamine and of di-t-butylcarbonate in methanol
was stirred for 4 hrs and then concentrated by rotary evaporation to afford brown
oil. Pure white solid was obtained from column chromatography.
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tert-butyl (2-(phenylamino)ethyl)carbamate (34)
1

H NMR (400 MHz, CDCl3 į-7.18 (m, 2H), 6.81-6.6 (m, 2H), 3.38-3.36 (d,
J=7.6 Hz, 2H), 3.27-3.23 (t, J=8.0 Hz, 2H), 1.48 (s, 9H)
A solution of SM, and triethylamine in dichloromethane was cooled to 0 oC.
Chloroacetyl chloride was added dropwise and the reaction was maintained at
0oC with stirring. After 3 hrs, another portion of chloroacetyl chloride was added
dropwise. After 30 min, the reaction was poured into ethyl acetate and washed
with water, saturated aqueous ammonium chloride, saturated aqueous sodium
bicarbonate solution and brine. The solution was dried over sodium sulfate,
filtered and concentrated in vacuum giving brown oil, chloroacetamide.Yield,
48%.
tert-butyl (2-((chlorocarbonyl)(phenyl)amino)ethyl)carbamate (35)
1

H NMR (400 MHz, CDCl3  į -7.41 (m, 3H), 7.28-7.27 (d, J=6.6 Hz, 2H),
3.87-3.83 (m, 4H), 3.35-3.34 (d, J=5.44 Hz, 2H), 1.4165 (s, 9H)
An oven dried two-mouthed flask equipped with a magnetic stirrer was evacuated
while hot and cooled under nitrogen. The tube was charged with palladium
acetate (5%), 2-(di-tert-butylphosphino) biphenyl (Pd: ligand = 2:1), and
chloroacetanilide (1 mmol). The tube was evacuated and backfilled with nitrogen.
Anhydrous triethylamine (1.5 mmol) was added, followed by anhydrous
anhydrous toluene (1.0 mL). The septum was replaced was replaced under a
positive pressure of nitrogen, and the sealed tube was placed in an oil bath
preheated to 80oC. After 16 hours, the reaction was allowed to cool to room
temperature and was diluted with ethyl acetate (10 mL). The mixture was filtered
through a plug of Celite and concentrated on a rotary evaporator. The crude
material thus obtained was purified by silica gel chromatography to give product
oxindole. Yield, 65%.
tert-butyl (2-(2-oxoindolin-1-yl)ethyl)carbamate (36):
1H NMR (400 MHz, CDCl3  į -7.21 (m, 2H), 7.04-7.00 (t, J=7.5 Hz, 1H),
6.96-6.93 (d, 7.8 Hz,1H), 4.14-4.07 (d, J= 7.2 Hz, 2H), 3.86-3.82 (t, J= 8.0Hz,
2H), 3.39-3.35 (q, J=5.7 Hz, 2H), 1.40( s, 9H).
Various aldehydes (1.5 mmol) and piperidine (0.3 mmol) were added to a
suspension of oxindole (1 mmol) in ethanol (15 mL). The solution was heated at
80oC for 1.5 hours. The reaction was allowed to cool to room temperature. The
precipitate was filtered, was in ethanol. The Boc-protected compound (1 mmol)
was dissolved in ethylacetate (3 mL). Dioxane-HCl (1 mmol) was added to the
flask and the reaction was stirred for 2 hrs. Solid suspension was observed, the
mixture was filtered and the collected solid washed with ethyl acetate and ether.
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1-(2-aminoethyl)-3-(3-phenylpropylidene)indolin-2-one (2): 1H NMR (400
0+]'062 į V+ -7.65 (d, J=7.52 Hz, 1H), 7.35- 7.2890 (m, 5H),
7.23-7.20 (m, 2H), 7.10-7.06 (t, J=6.96 Hz, 1H), 6.90-6.86 (t, J=7.24 Hz, 1H),
4.00-3.96 (t, J=6.48 Hz, 2H), 3.05- 2.99 (m, 4H), 2.95-2.91 (m, 2H).
13

C NMR (100 MHz, DMSO): 167.0, 142.1, 140.7, 129.1, 128.4, 127.3, 126.1,
123.6, 122.2, 121.6, 108.7, 37.0, 36.6, 33.7, 30.1

1-(2-aminoethyl)-3-(3-cyclohexylpropylidene)indolin-2-one  (3): 1H NMR (400
0+]'062 į V+ -7.63 (d, J=7.48, 1H), 7.35-7.31 (t, J=7.2 Hz,
1H), 7.22-7.20 (d, J=7.72 Hz, 1H), 7.11-7.07 (t, J=8.16 Hz, 1H), 6.90-6.86 (t,
J=7.76 Hz, 1H), 4.01-3.98 (t, J=6.48, 2H), 3.03-3.00 (m, 2H), 2.71-2.65 (q, J=
7.64 Hz, 2H), 1.74-1.51 (m, 5H), 1.49-1.39 (q, J=7.56 Hz, 2H), 1.26-1.11 (m, 4H),
0.97-0.88 (m, 2H)
13

C NMR (100 MHz, DMSO): 167.1, 142.2, 142.2, 128.9, 128.4, 126.8, 123.4,
122.2, 121.8, 108.7, 36.8, 36.7, 35.5, 32.6, 30.7, 26.1, 25.7
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1-(2-aminoethyl)-3-(3-cyclopropylpropylidene)indolin-2-one (4) 1H NMR (400
0+]0H2' į-7.33 (d, J= 6.88 Hz, 1H), 7.35-7.33 (t, J=6.84 Hz, 1H), 7.167.07 (m, 3H), 4.11-4.08 (t, J=6.00 Hz, 2H), 3.27-3.24 (t, J=5.72 Hz, 3H) 2.88-2.83
(q, J=7.44 Hz, 2H), 1.60-1.55 (q, J=7.16 Hz, 2H), 0.51-0.46 (m, 2H), 0.16-0.12
(m, 2H)
13

C NMR (100 MHz, DMSO): 170.5, 144.4, 143.1, 130.2, 128.5, 125.1, 124.0,
123.7, 109.4, 39.3, 38.7, 34.8, 30.6, 11.7, 5.2.

3-(3-((3r,5r,7r)-adamantan-1-yl)propylidene)-1-(2-aminoethyl)indolin-2-one
(5)
1

+105 0+]'062 į V+ -7.61 (d, J= 7.52 Hz, 1H), 7.357.31 (t, J=7.72 Hz, 1H), 7.22-7.20 (d, J=7.84 Hz, 1H), 7.12-7.09 (t, J=7.52 Hz,
1H), 6.91-6.87 (t J=7.84 Hz, 1H), 4.00-3.97 (t, J=6.56, 2H), 3.04-3.00 (q, J=5.44,
2H), 2.65-2.59 (q, J=8.04 Hz, 2H), 1.99 (s, 3H), 1.71-1.60 (q, J=12.04 Hz, 6H),
1.54 (s, 6H), 1.36-1.32 (m, 2H).
13

C NMR (100 MHz, DMSO): 167.0, 157.1, 142.1, 140.9, 132.4, 129.3, 129.0,
127.2, 123.5, 122.2, 121.6, 114.4, 114.3, 108.7, 67.0, 66.3, 37.0, 36.6, 32.8,
30.8, 30.4, 18.7, 13.7.
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1-(2-aminoethyl)-3-nonylideneindolin-2-one (6): 1H NMR (400 MHz, DMSO):
į V+ -7.65 (d, J= 7.56, 1H), 7.34-7.17 (t, J=7.68, 1H), 7.17-7.16 (d,
J=7.8, 3H), 7.11-7.07 (t, J=7.56, 1H), 6.91-6.87 (t, J=7.80, 1H), 3.99-3.96 (t,
J=6.32, 2H),2.71-2.65 (q, J=7.40, 2H), 1.61-1.57 (m, 2H), 1.39-1.26 (m, 11H),
0.87-0.83 (t, J=6.60, 3H).
13

C NMR (100 MHz, DMSO): 142.1, 129.0, 127.0, 123.5, 122.2, 121.7, 36.8,
31.2, 28.8, 28.6, 28.0, 22.0, 13.9.

1-(2-aminoethyl)-3-(3-(4-methoxyphenyl)propylidene)indolin-2-one (7) 1H
NMR (400 MHz, '062 į V+ -7.64 (d, J= 7.48, 1H), 7.35-7.31 (t,
J=7.72, 1H), 7.24-7.20 (t, J=8.48, 3H), 7.10-7.06 (t, J=7.60, 1H), 6.89-6.85 (m,
3H), 4.00-3.96 (t, J=6.52, 2H), 3.01-2.95 (m, 4H), 2.88-2.85 (t, J=6.92, 2H), 2.512.49 (m, 3H)
13

C NMR (100 MHz, DMSO): 167.0, 157.7, 142.1, 141.9, 140.9, 140.6, 132.6,
129.3, 129.2, 129.1, 128.7, 127.2, 123.5, 122.2, 121.8, 121.6, 119.4, 113.8,
108.7, 108.4, 55.0, 37.0, 36.8, 36.8, 36.6, 33.4, 32.8, 30.4, 30.4, 29.3
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1-(2-aminoethyl)-3-(3-(4-ethoxyphenyl)propylidene)indolin-2-one (8) 1H NMR
 0+] '062  į  V +  -7.64 (d, J= 7.48, 1H), 7.33-7.31 (t,
J=7.72 Hz, 1H), 7.24-7.20 (m, 3H), 7.10-7.06 (t, J=7.60 Hz, 1H), 6.89-6.85 (m,
3H), 4.00-3.96 (t, J=6.52, 2H), 4.00-3.96 (t, J=6.52 Hz, 3H), 3.01-2.95(m, 4H),
2.88-2.85 (t, J=6.92 Hz, 2H), 2.51-2.49 (m, 3H)
3

C NMR (100 MHz, DMSO): 167.1, 142.1, 132.4, 129.3, 129.0, 127.2, 123.6,
121.7, 114.2, 108.6, 62.9, 37.1, 36.8, 32.8, 30.4, 14.7

1-(2-aminoethyl)-3-(3-(4-butoxyphenyl)propylidene)indolin-2-one (9) 1H NMR
(400 MHz, DMSO): į  V +  -7.64 (d, J= 7.48 Hz, 1H), 7.35-7.31 (t,
J=7.72 Hz, 1H), 7.22-7.16 (m, 3H), 7.08-7.07 (t, J=6.92 Hz, 1H), 6.89-6.84 (m,
3H), 4.00-3.97 (t, J=6.56 Hz, 2H),3.94-3.91 (t, J=6.44 Hz, 3H), 3.03-2.95(m, 4H),
2.87-2.84 (t, J=6.96, 2H),1.70-1.63 (m, 2H), 1.45-1.39 (m, 2H), 0.94-0.90 (t,
J=7.36 Hz, 3H)
13

C NMR (100 MHz, DMSO): 167.1, 142.9, 142.1, 128.9, 126.5, 123.3, 122.2,
121.7, 108.7, 66.3, 108.7, 37.0, 36.7, 36.6, 36.5, 32.0, 28.0, 22.4
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1-(2-aminoethyl)-3-(3-(4-(heptyloxy)phenyl)propylidene)indolin-2-one (10)
1

H 105 0+]'062 į V+ -7.64 (d, J= 7.48 Hz, 1H), 7.357.31 (t, J=7.72 Hz, 1H), 7.22-7.18 (m, 3H), 7.10-7.06 (t, J=7.56 Hz, 1H), 6.896.84 (m, 3H), 3.99-3.95 (t, J=6.32, 2H), 3.93-3.90 (t, J=6.52 Hz, 3H), 3.02-2.95
(m, 4H), 2.87-2.84 (t, J=7.04 Hz, 2H),1.72-1.65 (m, 2H), 1.43-1.17 (m, 8H), 0.880.85 (t, J=6.64 Hz, 3H)
3

C NMR (100 MHz, DMSO): 167.0, 157.1, 142.1, 140.9, 132.4, 129.3, 129.0,
127.2, 123.6, 122.2, 121.7, 114.4, 108.6, 37.0, 36.7, 32.8, 31.2, 30.4, 28.7, 28.7,
28.4, 25.5, 22.0, 13.9.

1-(2-aminoethyl)-3-(3-(4-fluorophenyl)propylidene)indolin-2-one
105  0+] 0H2' į -7.64 (d, J=7.56, 1H), 7.35- 7.27 (m,
6.97 (m, 5H), 7.10-7.06 (t, J=6.96 Hz, 1H), 6.90-6.86 (t, J=7.24 Hz,
4.06 (t, J=5.88 Hz, 2H), 3.26- 3.23 (t, J=6.12 Hz, 2H), 3.08-3.03 (m,
2.95 (m, 2H).
13

(11): 1H
3H), 7.131H), 4.092H), 2.99-

C NMR (100 MHz, DMSO): 170.0, 164.2, 161.8, 143.1, 138.0, 131.2, 130.4,
129.0, 125.0, 124.1, 123.5, 116.3, 116.1, 109.5, 39.3, 38.7, 34.6, 32.1
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1-(2-aminoethyl)-3-(3-(4-chlorophenyl)propylidene)indolin-2-one (12) 1H
105 0+]'062 į V+  7.67-7.65 (d, J=7.52 Hz, 1H), 7.36- 7.32
(m, 5H), 7.17-7.15 (d, J=7.80 Hz, 2H), 7.10-7.06 (t, J=6.96 Hz, 1H), 6.87-6.84 (t,
J=7.04 Hz, 1H), 3.98-3.94 (t, J=6.28 Hz, 2H), 3.04- 2.99 (m, 4H), 2.95-2.91 (m,
2H).
13

C NMR (100 MHz, DMSO): 140.4, 139.8, 130.7, 129.1, 128.3, 127.4, 123.6,
122.2, 121.6, 108.7, 37.1, 36.7, 33.0, 29.9

1-(2-aminoethyl)-3-(3-(4-nitrophenyl)propylidene)indolin-2-one (13)
1

+105 0+]0H2' į-8.74 (d, J=7.48 Hz, 3H), 7.67-7.65 (d, J=7.52
Hz, 1H), 7.35- 7.2890 (m, 5H), 7.23-7.20 (m, 2H), 7.10-7.06 (t, J=6.96 Hz, 1H),
6.90-6.86 (t, J=7.24 Hz, 1H), 4.00-3.96 (t, J=6.48 Hz, 2H), 3.05- 2.99 (m, 4H),
2.95-2.91 (m, 2H).
13

&105 0+]'062 į
124.2, 123.2, 115.6, 109.5, 37.9, 38.7, 26.6, 32.1
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5.1 Cell Proliferative Assay
The technique is based on the tetrazolium ring of 3-[4, 5-dimethylthiazol-2yl]-2, 5-diphenyltetrazolium (MTT) that is cleaved by mitochondria reductase in
living cells to produce a purple formazan. The purple formazan dissolved in
DMSO is quantified at 540 nm. The assay reflects the number of viable cells,
since reduction can only be stimulated by activated mitochondrial enzyme. The
U937 cells were seeded at a density of 2 X10 5, and 100 PL of cells were added
per well in a 96-well plate with a multi-channel pipette. The cells were treated
with 100 PL of active compounds at the concentration: 0, 1, 3, 10 and 30 PL. 10
PL of 5mg/ mL of (3-(4,5-Dimethylthiazol -2-yl)-2,5-diphenyltetrazolium

bromide was added to each well and allowed to incubate at 37oC in a fully
humidified atmosphere containing 5% CO2. After which 170 PL of medium
was extracted from each well, and 100 PL DMSO was added and mixed
thoroughly to ensure homogeneity. The intracellular soluble formazan produced
by the cellular reduction of the MTT was determined by recording the absorbance
of each 96-well plate using the automatic microlplate photometer (Flexstation3,
Molecular Device, USA) at wavelength 570 nm. The values were expressed as
percentage relative to those obtained in untreated controls. The IC50 was
determined by constructing a dose-response curve.
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5.2 Western Blot Assay
Cells (5 X105/mL) were pretreated with compounds for 1 h, prior to being
lysed by sonication in 1x sample buffer [62.5 mM Tris base (pH 6.8), 2% SDS, 50
mM DTT, 10% glycerol, 0.1% bromphenol blue, and 5 mg/mL each chymostatin,
leupeptin, aprotinin, pepstatin, and soybean trypsin inhibitor] and boiled for 5 min.
For analysis of phosphoproteins, 1 mM of sodium orthovanadate and sodium
pyrophosphate was added to the sample buffer. Protein samples were collected
from the supernatant after centrifugation of the samples at 12,800 g for 5 min,
and protein was quantified using Coomassie Protein Assay Reagent.
Equal amounts of protein (30.0 mg) were separated by SDS-PAGE on 410% tris/glycine gel (Bio-Rad) and electrotransferred onto a PVDF membrane
(Bio-Rad). For blotting phospho-proteins, no SDS was included in the transfer
buffer. The blots were blocked with 5% milk in TBS-Tween 20 (0.1%) at 25oC for
1 h and probed with the appropriate dilution of primary antibody overnight at 4
o

C. The blots were washed twice in TBS-Tween 20 for 15 min then incubated

with a 1:2000 dilution of horseradish peroxidase conjugated secondary antibody
in 5% milk/PBS-Tween 20 at 25oC for 1 h. After washing twice in TBS-Tween 20
for 15 min, the proteins were visualized by Western Blot Chemiluminescence
Reagent. The primary antibodies used: Phospho-p44/42 MAPK (Thr202/Tyr204)
antibody (1:1000, rabbit polyclonal, p44/42 MAPK antibody (1:1000, rabbit
polyclonal), phospho-MEK1/2 (1:1000, rabbit polyclonal), MEK1/2 (1:1000, rabbit
polyclonal),

phospho-Akt(Ser473)

(1:1000,
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rabbit polyclonal),(1:1000,rabbit

polyclonal), Akt1/2/3 (H-136)

(1:1000, rabbit polyclonal).

5.3 Apoptosis assay  
After treatment with compounds at indicated concentrations for 24 hours,
cells were washed twice with cold PBS and then
buffer

(10

mM

ethanesulfonicacid]/NaOH, pH

HEPES
7.4,

suspended in 1x binding
[N-2-hydroxyethylpiperazine-N-

140 mM NaOH, 2.5 mM CaCl2). The

cells were incubated with annexin V fluorescein isothiocyanate (FITC) and
5mg/mL propidium iodide (PI), and incubated for 15 min at room temperature in
the dark per the manufacturer¶s

instructions. The samples were analyzed by

flow cytometry using a Becton Dickinson FACScan within 1 h to determine the
percentage of cells displaying annexin V staining (early apoptosis) or both
annexin V and PI staining (late apoptosis).
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